<ѻý>C3 Inhibitor Prevails in Trial of Rare Hemoglobinuriaѻý> Improvement in hemoglobin, transfusion independence with pegcetacoplan for PNH Mar 17, 2021
<ѻý>Time to Revisit Distant Nodal Status in Breast Cancer Curability?ѻý> Comparable survival for distant and regional nodal involvement, when treated similarly Mar 16, 2021
<ѻý>Holding tPA for All DOAC Users Not the Way to Go, Stroke Docs Sayѻý> Clinical conundrum could be solved by a point-of-care DOAC test Mar 15, 2021
<ѻý>Whole-Genome Sequencing Makes a Case in Leukemia Studyѻý> More actionable alterations detected in myeloid malignancies versus cytogenetics Mar 10, 2021
<ѻý>Study Confirms Risk-Adapted CRS Prophylaxis for Acute Leukemiaѻý> Tocilizumab reduced severe cytokine release syndrome in children, young adults Mar 09, 2021
<ѻý>New Guideline Lowers Age to Begin Colorectal Cancer Screeningѻý> Update comes as incidence has doubled in people under 50 Mar 09, 2021
<ѻý>USPSTF Expands Lung Cancer Screening Criteriaѻý> Lower age for starting, new definition of 'heavy smoker' double eligibility for screening Mar 09, 2021
<ѻý>PD-1 Inhibitor Falls Short in Triple-Negative Breast Cancerѻý> No survival benefit with pembrolizumab vs chemotherapy in second-, third-line treatment Mar 08, 2021
<ѻý>Entrectinib Impresses in Certain Lung Cancersѻý> Durable responses in most patients with advanced NSCLC, active in brain mets Mar 05, 2021
<ѻý>New Targeted Therapies Show Promise in Cancerѻý> Selected abstracts from the ESMO Targeted Anticancer Therapies virtual meeting Mar 03, 2021
<ѻý>Mammo Study: One Saves Lives, More Exams Save More Livesѻý> Risk of fatal breast cancer decreases with increasing participation in screening Mar 02, 2021
<ѻý>Neoadjuvant Dual ICI Leads to Clinical Benefit in Operable NSCLCѻý> More than one-third of patients achieved major pathologic response with nivolumab-ipilimumab. Feb 18, 2021
<ѻý>A CLEAR Upfront Winner in Advanced RCC?ѻý> Pembrolizumab-lenvatinib makes splash with longest PFS benefit in RCC recorded to date Feb 14, 2021
<ѻý>Practice-Changing Trial in Metastatic Papillary RCCѻý> Cabozantinib improved PFS, response rates over sunitinib Feb 14, 2021
<ѻý>New Standard in High-Risk Muscle-Invasive Bladder Cancer?ѻý> Adjuvant nivolumab improves DFS in all comers, PD-L1 population Feb 13, 2021
<ѻý>New Drug OK'd for Chemo-Induced Myelosuppression in SCLCѻý> CDK4/6 inhibitor cut the risk for severe neutropenia in small-cell lung cancer patients Feb 13, 2021
<ѻý>CCR Score Could Offer ADT-Free Path in Higher-Risk Prostate Cancerѻý> Large proportion of intermediate- to high-risk patients could avoid aggressive therapy Feb 12, 2021
<ѻý>Survival Boost in Bladder Cancer With Antibody-Drug Conjugateѻý> Four-month absolute improvement with enfortumab vedotin in previously treated disease Feb 12, 2021
<ѻý>Radionuclide Tx Wins in Third-Line Metastatic CRPCѻý> Early trial shows improved PFS, response rates versus cabazitaxel Feb 11, 2021
<ѻý>Hit and Miss in Castration-Resistant Prostate Cancerѻý> No OS benefit with apalutamide-abiraterone, despite improved PFS Feb 11, 2021
<ѻý>Want Data on Recently Approved Actinic Keratosis Drug? Here You Goѻý> Phase III trial now published in full for topical anti-proliferative treatment Feb 10, 2021
<ѻý>First Immunotherapy Approved for Basal Cell Carcinomaѻý> Objective responses in 27% of previously treated patients who received cemiplimab Feb 10, 2021
<ѻý>FDA Panel Slows the Roll for Pembrolizumab in Breast Cancerѻý> Advisory committee: Wait for more data before considering neoadjuvant indication Feb 09, 2021
<ѻý>Has Pembrolizumab Finally Met an Indication FDA Doesn't Like?ѻý> Agency staff skeptical of data in early breast cancer Feb 08, 2021
<ѻý>Anti-CD20 Drugs Tied to Severe COVID in Cancer Patientsѻý> Plus: Active chemo treatment may not be a COVID risk factor Feb 05, 2021
<ѻý>Brain Tumor Risk Upped With Synthetic Progestogenѻý> Absolute risk still low, however, and product not currently approved in U.S. Feb 03, 2021
<ѻý>Optimizing Neoadjuvant Therapy for Breast Cancerѻý> ASCO guideline covers patient selection, treatment options, follow-up Feb 02, 2021
<ѻý>Dustin Diamond's Small Cell Lung Cancerѻý> "Saved by the Bell" actor diagnosed after exhaustive testing Feb 02, 2021
<ѻý>KRAS Inhibitor Continues to Impress in NSCLCѻý> Sotorasib yielded deep and durable responses in over one-third of patients Feb 01, 2021
<ѻý>Nab-Paclitaxel as Possible Option for Relapsed NSCLCѻý> Noninferior to docetaxel for OS, though impact on clinical practice questioned Feb 01, 2021
<ѻý>AGA Updates Guidelines for Refractory H. Pyloriѻý> New info stresses knowing patients' antibiotic exposure and doing drug susceptibility testing Feb 01, 2021
<ѻý>Should COVID-Strained Centers Hit Pause on Lung Cancer Screening?ѻý> A debate on what stopping scans would do to health systems, patients Feb 01, 2021
<ѻý>Promising Data for Preop Checkpoint Inhibition in NSCLCѻý> Major response rate of 21%, encouraging survival with single-agent atezolizumab Jan 31, 2021
<ѻý>First-Ever Survival Bump in Relapsed Mesotheliomaѻý> OS, PFS improved with nivolumab, but questions remain about alternatives, biomarkers Jan 30, 2021
<ѻý>Dual Checkpoint Blockade No Help in PD-L1-High NSCLCѻý> Single-agent pembrolizumab wins out as first-line therapy for advanced disease Jan 30, 2021
<ѻý>COVID Affects Cancer Care, Patients' Mental Healthѻý> Studies: fewer diagnoses, more severe disease, worse outcomes, distressed patients Jan 29, 2021
<ѻý>Preventive Approach to C-Section Bleeding Pans Out in Trialѻý> Treatment lowered risk of early blood loss and transfusion, but not more severe hemorrhage Jan 29, 2021
<ѻý>Whole-Pelvis Tops Prostate-Only RT in High-Risk Diseaseѻý> Practice impact may hinge on knowledge versus clinical bias Jan 28, 2021
<ѻý>Officials Investigate Physician's Death After COVID Vaccinationѻý> Onset of rare blood disorder should not be interpreted as causal, experts say Jan 27, 2021